Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kyverna Therapeutics, Inc. (KYTX)
USD7.82
-0.12 (-1.51%)
US NASDAQ Healthcare Biotechnology
Address
5980 Horton Street 94608
Emeryville, CA, US
Emeryville, CA, US
CEO
Warner Biddle
Website
kyvernatx.com
IPO
2024-02-09
CIK 1994702 ISIN US5019761049
Description
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
News Sentiment (7d)
Based on only 2 articles — low confidence
- Kyverna Therapeutics Sinks 13%: Here's Why 24/7 Wall Street
- Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS Seeking Alpha
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD7.82
-0.12 (-1.51%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.96
Float Shares
19.83M
Free Float %
45.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.06% | +9.41% | +7.80% | +40.91% | +57.87% | +8.83% | +340.95% | -65.90% | -65.90% | -65.90% | -65.90% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
7.82
Low
32.00
+309.2%
Consensus
32.67
+317.8%
Median
33.00
+322.0%
High
33.00
+322.0%
DCF (Unlevered)
2.04
-73.9%
DCF (Levered)
2.15
-72.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 6 |
25.50
+226.1%
|
| All Time | 6 |
25.50
+226.1%
|
Quality scores
Altman Z-Score
0.79
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-9.3% Q1'26: +35.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+15.5% Q1'26: +39.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.17× Q1'26: -0.05× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 5 EPS Ana. |
Dec 2027 4 Rev. Ana. 5 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 3.75M (-100.0%)
|
—
est: 6.67M (-100.0%)
|
12.50M
3.03M – 26.49M
+87.5% YoY
|
16.15M
3.92M – 34.23M
+29.2% YoY
|
53.17M
53.17M – 53.17M
+229.2% YoY
|
174.55M
42.33M – 369.87M
+228.3% YoY
|
523.75M
127.02M – 1.11B
+200.1% YoY
|
| EBITDA |
-125.20M
est: 750.0K (-16,793.6%)
|
-167.38M
est: 1.33M (-12,653.5%)
|
2.50M
606.3K – 5.30M
+87.5% YoY
|
3.23M
783.5K – 6.85M
+29.2% YoY
|
10.63M
10.63M – 10.63M
+229.2% YoY
|
34.91M
8.47M – 73.97M
+228.3% YoY
|
104.75M
25.40M – 221.97M
+200.1% YoY
|
| EBIT |
-127.34M
est: 750.0K (-17,078.0%)
|
-169.18M
est: 1.33M (-12,788.4%)
|
2.50M
606.3K – 5.30M
+87.5% YoY
|
3.23M
783.5K – 6.85M
+29.2% YoY
|
10.63M
10.63M – 10.63M
+229.2% YoY
|
34.91M
8.47M – 73.97M
+228.3% YoY
|
104.75M
25.40M – 221.97M
+200.1% YoY
|
| Net Income |
-127.48M
est: -145.42M (+12.3%)
|
-161.31M
est: -161.31M (+0.0%)
|
-134.08M
-157.24M – -110.92M
+16.9% YoY
|
-135.35M
-158.86M – -111.84M
-0.9% YoY
|
-105.59M
-121.12M – -90.06M
+22.0% YoY
|
-159.34M
-391.12M – -2.44M
-50.9% YoY
|
-47.36M
-116.25M – -723.9K
+70.3% YoY
|
| SGA |
30.13M
est: 3.92M (+668.6%)
|
36.11M
est: 6.97M (+418.1%)
|
13.07M
3.17M – 27.69M
+87.5% YoY
|
16.89M
4.10M – 35.78M
+29.2% YoY
|
55.59M
55.59M – 55.59M
+229.2% YoY
|
182.48M
44.26M – 386.67M
+228.3% YoY
|
547.54M
132.79M – 1.16B
+200.1% YoY
|
| EPS |
-3.33
est: -3.30 (-1.0%)
|
-3.64
est: -3.69 (+1.5%)
|
-3.05
-3.55 – -2.51
+17.3% YoY
|
-2.98
-3.59 – -2.53
+2.5% YoY
|
-2.44
-2.74 – -2.03
+18.1% YoY
|
-3.60
-8.84 – -0.06
-47.6% YoY
|
-1.07
-2.63 – -0.02
+70.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-23 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-153.71M
OE per share TTM
-3.49
Owner's Yield
-31.52%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
370.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
20
Total invested
27.40M
Insider transactions (90d)
1
Beneficial owners (>5%)
20
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VV Manager LLC | 4.78M | 11.10% | — | 4.78M | — | 4.78M | OO | Delaware | 2024-05-03 | ↗ |
| 2 | Vida Ventures, LLC | 4.78M | 11.10% | — | 4.78M | — | 4.78M | OO | Nevada | 2024-05-03 | ↗ |
| 3 | Dr. Beth C. Seidenberg (“Seidenberg”) | 4.52M | 10.50% | — | 4.52M | — | — | IN | Delaware | 2024-11-12 | ↗ |
| 4 | Dr. Sean E. Harper (“Harper”) | 4.52M | 10.50% | — | 4.52M | — | — | IN | Delaware | 2024-11-12 | ↗ |
| 5 | Fred Cohen | 4.52M | 10.50% | — | 4.52M | — | 4.52M | IN | United States of America | 2024-05-03 | ↗ |
| 6 | Gilead Sciences, Inc. | 4.13M | 9.60% | 4.13M | — | 4.13M | — | CO | Delaware | 2024-02-20 | ↗ |
| 7 | Westlake BioPartners Fund I, L.P. (“Westlake Fund I”) | 3.79M | 8.80% | 3.79M | — | 3.79M | — | PN | Delaware | 2024-11-12 | ↗ |
| 8 | Westlake BioPartners GP I, LLC (“Westlake GP I”) | 3.79M | 8.80% | 3.79M | — | 3.79M | — | OO | Delaware | 2024-11-12 | ↗ |
| 9 | Michael P. Rubin | 3.26M | 7.60% | — | 3.26M | — | — | IN | Delaware | 2024-02-22 | ↗ |
| 10 | Bain Capital Life Sciences Opportunities III, LP | 3.16M | 7.40% | — | 3.16M | — | 3.16M | PN | Delaware | 2024-02-14 | ↗ |
| 11 | Northpond Ventures III GP, LLC | 2.81M | 6.50% | — | 2.81M | — | — | OO | Delaware | 2024-02-22 | ↗ |
| 12 | Northpond Ventures III, LP | 2.81M | 6.50% | — | 2.81M | — | — | PN | Delaware | 2024-02-22 | ↗ |
| 13 | JPMORGAN CHASE & CO.13-2624428 | 2.38M | 5.50% | 2.04M | — | 2.38M | — | HC | Delaware | 2024-10-10 | ↗ |
| 14 | Westlake BioPartners Opportunity Fund I, L.P. (“Westlake Opportunity Fund I”) | 736.0K | 1.70% | 736.0K | — | 736.0K | — | PN | Delaware | 2024-11-12 | ↗ |
| 15 | Westlake BioPartners Opportunity GP I, LLC (“Westlake Opportunity GP I”) | 736.0K | 1.70% | 736.0K | — | 736.0K | — | OO | Delaware | 2024-11-12 | ↗ |
| 16 | Northpond Ventures GP, LLC | 450.0K | 1.00% | — | 450.0K | — | — | OO | Delaware | 2024-02-22 | ↗ |
| 17 | Northpond Ventures, LP | 450.0K | 1.00% | — | 450.0K | — | — | PN | Delaware | 2024-02-22 | ↗ |
| 18 | Vida Ventures GP III, L.L.C. | 253.1K | 0.60% | — | 253.1K | — | 253.1K | OO | Delaware | 2024-05-03 | ↗ |
| 19 | Vida Ventures III, L.P. | 252.6K | 0.60% | — | 252.6K | — | 252.6K | PN | Delaware | 2024-05-03 | ↗ |
| 20 | Vida Ventures III-A, L.P. | 583.00 | 0.00% | — | 583.00 | — | 583.00 | PN | Delaware | 2024-05-03 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
20
-86 vs prev Q
New positions
5
Closed positions
85
Increased
12
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 4.39M +4.4M (+100.0%) | 41.28B +41.3B (+100.0%) | 10.12% +10.116 pp | 29.60% +29.595 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 2 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 53.5K +53.5K (+100.0%) | 502.90M +502.9M (+100.0%) | 0.12% +0.123 pp | 0.43% +0.429 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 3 | GILEAD SCIENCES, INC. | 4.13M +— (+0.0%) | 38.79M +14.0M (+56.7%) | 9.50% -0.042 pp | 2.00% +0.622 pp | USD3.74 +151.3% | 5 qtrs — |
| 4 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 3.11M -258.4K (-7.7%) | 29.23M +9.0M (+44.6%) | 7.16% -0.629 pp | 2.24% +0.898 pp | USD21.63 -56.5% | 8 qtrs — |
| 5 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2.00M +2.0M (+100.0%) | 18.80M +18.8M (+100.0%) | 4.61% +4.607 pp | 0.24% +0.240 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 6 | VANGUARD GROUP INC | 1.78M +458.6K (+34.7%) | 16.74M +8.8M (+111.0%) | 4.10% +1.043 pp | 0.00% +0.000 pp | USD9.62 -2.3% | 8 qtrs — |
| 7 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.76M +250.4K (+16.6%) | 16.57M +7.5M (+82.6%) | 4.06% +0.562 pp | 0.00% +0.001 pp | USD9.25 +1.6% | 8 qtrs — |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.67M +1.7M (+100.0%) | 15.67M +15.7M (+100.0%) | 3.84% +3.839 pp | 0.02% +0.024 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 9 | AIGH CAPITAL MANAGEMENT LLC | 1.50M +1.5M (+100.0%) | 14.10M +14.1M (+100.0%) | 3.46% +3.455 pp | 3.41% +3.413 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 10 | MORGAN STANLEY | 1.00M +828.3K (+475.5%) | 9.42M +8.4M (+801.6%) | 2.31% +1.906 pp | 0.00% +0.001 pp | USD9.00 +4.4% | 8 qtrs — |
| 11 | INSIGHT HOLDINGS GROUP, LLC | 989.1K +— (+0.0%) | 9.30M +3.4M (+56.7%) | 2.28% -0.010 pp | 0.70% +0.329 pp | USD20.93 -55.1% | 8 qtrs — |
| 12 | BALYASNY ASSET MANAGEMENT L.P. | 980.9K +980.9K (+100.0%) | 9.22M +9.2M (+100.0%) | 2.26% +2.259 pp | 0.01% +0.012 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 13 | WOODLINE PARTNERS LP | 845.1K +592.9K (+235.1%) | 7.94M +6.4M (+425.0%) | 1.95% +1.363 pp | 0.03% +0.024 pp | USD8.39 +12.0% | 2 qtrs — |
| 14 | PROPEL BIO MANAGEMENT, LLC | 666.7K +666.7K (+100.0%) | 6.27M +6.3M (+100.0%) | 1.54% +1.536 pp | 5.35% +5.350 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 15 | MBB PUBLIC MARKETS I LLC | 614.5K +— (+0.0%) | 5.78M +2.1M (+56.7%) | 1.42% -0.006 pp | 0.60% +0.113 pp | USD6.84 +37.4% | 7 qtrs — |
| 16 | ALYESKA INVESTMENT GROUP, L.P. | 600.0K +600.0K (+100.0%) | 5.64M +5.6M (+100.0%) | 1.38% +1.382 pp | 0.02% +0.016 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 17 | MILLENNIUM MANAGEMENT LLC | 593.4K +41.7K (+7.6%) | 5.58M +2.3M (+68.5%) | 1.37% +0.091 pp | 0.00% +0.001 pp | USD8.87 +6.0% | 8 qtrs — |
| 18 | BLACKROCK, INC. | 544.5K +62.5K (+13.0%) | 5.12M +2.2M (+77.0%) | 1.25% +0.139 pp | 0.00% +0.000 pp | USD5.31 +77.0% | 6 qtrs — |
| 19 | D. E. SHAW & CO., INC. | 518.5K +518.5K (+100.0%) | 4.87M +4.9M (+100.0%) | 1.19% +1.194 pp | 0.00% +0.003 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 20 | RFG ADVISORY, LLC | 445.2K +445.2K (+100.0%) | 4.18M +4.2M (+100.0%) | 1.03% +1.025 pp | 0.08% +0.079 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 21 | CITADEL ADVISORS LLC | 275.4K +257.8K (+1,459.2%) | 2.59M +2.5M (+2,342.7%) | 0.63% +0.594 pp | 0.00% +0.000 pp | USD9.11 +3.2% | 8 qtrs — |
| 22 | HEIGHTS CAPITAL MANAGEMENT, INC | 271.8K +271.8K (+100.0%) | 2.56M +2.6M (+100.0%) | 0.63% +0.626 pp | 0.92% +0.916 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 23 | GEODE CAPITAL MANAGEMENT, LLC | 266.4K -11.9K (-4.3%) | 2.51M +835.4K (+50.0%) | 0.61% -0.030 pp | 0.00% +0.000 pp | USD10.99 -14.5% | 8 qtrs — |
| 24 | BNP PARIBAS ARBITRAGE, SNC | 252.2K +218.1K (+641.1%) | 2.37M +2.2M (+1,061.1%) | 0.58% +0.502 pp | 0.00% +0.001 pp | USD8.91 +5.5% | 7 qtrs — |
| 25 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 238.8K +36.1K (+17.8%) | 2.24M +1.0M (+84.6%) | 0.55% +0.081 pp | 0.00% +0.000 pp | USD5.56 +69.1% | 5 qtrs — |
| 26 | TD ASSET MANAGEMENT INC | 222.8K +58.0K (+35.2%) | 2.09M +1.1M (+111.8%) | 0.51% +0.132 pp | 0.00% +0.001 pp | USD5.97 +57.5% | 7 qtrs — |
| 27 | TWO SIGMA INVESTMENTS, LP | 205.3K +72.8K (+55.0%) | 1.93M +1.1M (+142.8%) | 0.47% +0.166 pp | 0.00% +0.002 pp | USD8.27 +13.7% | 8 qtrs — |
| 28 | UBS GROUP AG | 202.2K +44.8K (+28.4%) | 1.90M +956.0K (+101.2%) | 0.47% +0.102 pp | 0.00% +0.000 pp | USD6.02 +56.1% | 8 qtrs — |
| 29 | BURKEHILL GLOBAL MANAGEMENT, LP | 200.0K +200.0K (+100.0%) | 1.88M +1.9M (+100.0%) | 0.46% +0.461 pp | 0.12% +0.124 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 30 | MONASHEE INVESTMENT MANAGEMENT LLC | 195.0K +195.0K (+100.0%) | 1.83M +1.8M (+100.0%) | 0.45% +0.449 pp | 1.03% +1.033 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 31 | SIMPLIFY ASSET MANAGEMENT INC. | 192.3K +192.3K (+100.0%) | 1.81M +1.8M (+100.0%) | 0.44% +0.443 pp | 0.03% +0.030 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 32 | PEAPOD LANE CAPITAL LLC | 183.8K -134.9K (-42.3%) | 1.73M -184.3K (-9.6%) | 0.42% -0.314 pp | 1.47% -0.240 pp | USD1.93 +387.0% | 4 qtrs — |
| 33 | JANE STREET GROUP, LLC | 182.1K -16.8K (-8.4%) | 1.71M +518.6K (+43.5%) | 0.42% -0.041 pp | 0.00% +0.000 pp | USD4.71 +99.6% | 3 qtrs — |
| 34 | RENAISSANCE TECHNOLOGIES LLC | 177.9K +13.3K (+8.1%) | 1.67M +684.6K (+69.3%) | 0.41% +0.029 pp | 0.00% +0.001 pp | USD3.90 +141.0% | 5 qtrs — |
| 35 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 174.9K +— (+0.0%) | 1.64M +594.7K (+56.7%) | 0.40% -0.002 pp | 0.03% +0.012 pp | USD4.92 +91.1% | 5 qtrs — |
| 36 | BARCLAYS PLC | 164.7K +94.5K (+134.7%) | 1.55M +1.2M (+351.1%) | 0.38% +0.217 pp | 0.00% +0.000 pp | USD10.28 -8.6% | 8 qtrs — |
| 37 | MAVEN SECURITIES LTD | 146.4K +146.4K (+100.0%) | 1.38M +1.4M (+100.0%) | 0.34% +0.337 pp | 0.03% +0.030 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 38 | SQUAREPOINT OPS LLC | 138.9K +138.9K (+100.0%) | 1.31M +1.3M (+100.0%) | 0.32% +0.320 pp | 0.00% +0.001 pp | USD9.40 +0.0% | 5 qtrs — |
| 39 | MARSHALL WACE, LLP | 135.6K +135.6K (+100.0%) | 1.27M +1.3M (+100.0%) | 0.31% +0.312 pp | 0.00% +0.001 pp | USD9.40 +0.0% | 8 qtrs — |
| 40 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 134.5K +30.7K (+29.6%) | 1.26M +635.0K (+102.0%) | 0.31% +0.070 pp | 0.00% +0.001 pp | USD8.41 +11.8% | 8 qtrs — |
| 41 | GOLDMAN SACHS GROUP INC | 133.5K +90.4K (+209.6%) | 1.26M +996.4K (+385.0%) | 0.31% +0.208 pp | 0.00% +0.000 pp | USD8.12 +15.8% | 7 qtrs — |
| 42 | STIFEL FINANCIAL CORP | 125.8K +87.0K (+224.0%) | 1.18M +949.5K (+407.6%) | 0.29% +0.200 pp | 0.00% +0.001 pp | USD7.65 +22.9% | 5 qtrs — |
| 43 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 125.4K -152.0 (-0.1%) | 1.18M +425.5K (+56.5%) | 0.29% -0.002 pp | 0.00% +0.000 pp | USD13.91 -32.4% | 8 qtrs — |
| 44 | 683 CAPITAL MANAGEMENT, LLC | 114.9K +114.9K (+100.0%) | 1.08M +1.1M (+100.0%) | 0.26% +0.265 pp | 0.05% +0.047 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 45 | KERA CAPITAL PARTNERS, INC. | 132.6K -289.3K (-68.6%) | 1.06M -1.5M (-58.0%) | 0.31% -0.671 pp | 0.13% -0.249 pp | USD3.67 +156.1% | 5 qtrs — |
| 46 | JACOBS LEVY EQUITY MANAGEMENT, INC | 108.5K -39.2K (-26.5%) | 1.02M +133.9K (+15.1%) | 0.25% -0.092 pp | 0.00% +0.000 pp | USD6.00 +56.7% | 2 qtrs — |
| 47 | STATE STREET CORP | 91.3K +— (+0.0%) | 858.2K +310.4K (+56.7%) | 0.21% -0.001 pp | 0.00% +0.000 pp | USD9.11 +3.2% | 8 qtrs — |
| 48 | HUDSON BAY CAPITAL MANAGEMENT LP | 88.6K +88.6K (+100.0%) | 832.4K +832.4K (+100.0%) | 0.20% +0.204 pp | 0.00% +0.003 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 49 | JUMP FINANCIAL, LLC | 80.3K +80.3K (+100.0%) | 754.8K +754.8K (+100.0%) | 0.19% +0.185 pp | 0.01% +0.009 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 50 | DIMENSIONAL FUND ADVISORS LP | 78.4K +78.4K (+100.0%) | 737.1K +737.1K (+100.0%) | 0.18% +0.181 pp | 0.00% +0.000 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 51 | WELLS FARGO & COMPANY/MN | 74.9K +56.7K (+310.0%) | 704.5K +594.8K (+542.3%) | 0.17% +0.130 pp | 0.00% +0.000 pp | USD8.64 +8.8% | 8 qtrs — |
| 52 | VOYA INVESTMENT MANAGEMENT LLC | 68.1K +68.1K (+100.0%) | 640.5K +640.5K (+100.0%) | 0.16% +0.157 pp | 0.00% +0.001 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 53 | QUBE RESEARCH & TECHNOLOGIES LTD | 63.6K +26.9K (+73.4%) | 598.0K +377.8K (+171.6%) | 0.15% +0.062 pp | 0.00% +0.000 pp | USD6.79 +38.4% | 3 qtrs — |
| 54 | ADAR1 CAPITAL MANAGEMENT, LLC | 57.4K +57.4K (+100.0%) | 539.8K +539.8K (+100.0%) | 0.13% +0.132 pp | 0.04% +0.040 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 55 | QUADRATURE CAPITAL LTD | 57.4K +57.4K (+100.0%) | 539.3K +539.3K (+100.0%) | 0.13% +0.132 pp | 0.01% +0.006 pp | USD9.40 +0.0% | 4 qtrs — |
| 56 | NORTHERN TRUST CORP | 51.6K -106.0 (-0.2%) | 484.8K +174.7K (+56.3%) | 0.12% -0.001 pp | 0.00% +0.000 pp | USD7.30 +28.8% | 8 qtrs — |
| 57 | TWO SIGMA ADVISERS, LP | 49.4K -31.9K (-39.2%) | 464.4K -23.4K (-4.8%) | 0.11% -0.074 pp | 0.00% 0.000 pp | USD3.84 +144.8% | 6 qtrs — |
| 58 | AMERICAN CENTURY COMPANIES INC | 46.4K +14.2K (+44.0%) | 435.9K +242.6K (+125.6%) | 0.11% +0.032 pp | 0.00% +0.000 pp | USD7.04 +33.5% | 2 qtrs — |
| 59 | OMERS ADMINISTRATION CORP | 34.8K +34.8K (+100.0%) | 327.1K +327.1K (+100.0%) | 0.08% +0.080 pp | 0.00% +0.002 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 60 | POINT72 ASSET MANAGEMENT, L.P. | 32.2K +5.0K (+18.4%) | 302.5K +139.5K (+85.5%) | 0.07% +0.011 pp | 0.00% +0.000 pp | USD4.05 +132.1% | 3 qtrs — |
| 61 | JEFFERIES FINANCIAL GROUP INC. | 32.0K +15.7K (+96.3%) | 300.8K +203.0K (+207.6%) | 0.07% +0.036 pp | 0.00% +0.001 pp | USD7.67 +22.6% | 2 qtrs — |
| 62 | SCHONFELD STRATEGIC ADVISORS LLC | 28.9K +28.9K (+100.0%) | 271.4K +271.4K (+100.0%) | 0.07% +0.067 pp | 0.00% +0.001 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 63 | BANK OF AMERICA CORP /DE/ | 28.7K -36.3K (-55.8%) | 269.9K -119.9K (-30.8%) | 0.07% -0.084 pp | 0.00% +0.000 pp | USD6.85 +37.2% | 8 qtrs — |
| 64 | ACT CAPITAL MANAGEMENT, LLC | 25.1K +25.1K (+100.0%) | 235.9K +235.9K (+100.0%) | 0.06% +0.058 pp | 0.19% +0.191 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 65 | RAYMOND JAMES FINANCIAL INC | 25.1K +25.1K (+100.0%) | 235.8K +235.8K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.000 pp | USD9.40 +0.0% | 3 qtrs — |
| 66 | XTX TOPCO LTD | 23.3K -25.8K (-52.6%) | 218.9K -75.8K (-25.7%) | 0.05% -0.060 pp | 0.01% -0.010 pp | USD3.92 +139.8% | 7 qtrs — |
| 67 | DEKABANK DEUTSCHE GIROZENTRALE | 7.5K +— (+0.0%) | 197.0K +2.0K (+1.0%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD22.52 -58.3% | 8 qtrs — |
| 68 | FEDERATED HERMES, INC. | 20.7K +5.5K (+36.6%) | 194.6K +103.7K (+114.0%) | 0.05% +0.013 pp | 0.00% +0.000 pp | USD6.44 +46.0% | 7 qtrs — |
| 69 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 19.0K +155.0 (+0.8%) | 179.1K +65.7K (+58.0%) | 0.04% +0.000 pp | 0.00% +0.001 pp | USD2.22 +323.4% | 4 qtrs — |
| 70 | CAXTON CORP | 18.8K -4.2K (-18.3%) | 176.5K +38.6K (+28.0%) | 0.04% -0.010 pp | 4.12% +3.521 pp | USD17.95 -47.6% | 8 qtrs — |
| 71 | EMPOWERED FUNDS, LLC | 17.9K +17.9K (+100.0%) | 168.6K +168.6K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.001 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 72 | CAMBRIA INVESTMENT MANAGEMENT, L.P. | 17.9K +17.9K (+100.0%) | 168.6K +168.6K (+100.0%) | 0.04% +0.041 pp | 0.01% +0.010 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 73 | QUEST PARTNERS LLC | 16.3K +16.3K (+100.0%) | 153.6K +153.6K (+100.0%) | 0.04% +0.038 pp | 0.01% +0.009 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 74 | ETHIC INC. | 12.6K -2.7K (-17.9%) | 118.5K +26.4K (+28.7%) | 0.03% -0.007 pp | 0.00% +0.000 pp | USD3.07 +206.2% | 3 qtrs — |
| 75 | PHOENIX WEALTH ADVISORS | 12.3K +1.8K (+17.1%) | 115.6K +52.6K (+83.5%) | 0.03% +0.004 pp | 0.04% +0.020 pp | USD4.00 +135.0% | 3 qtrs — |
| 76 | CITIGROUP INC | 12.3K +9.0K (+270.5%) | 115.6K +95.7K (+480.5%) | 0.03% +0.021 pp | 0.00% +0.000 pp | USD9.29 +1.2% | 8 qtrs — |
| 77 | ENTRYPOINT CAPITAL, LLC | 10.0K +10.0K (+100.0%) | 94.5K +94.5K (+100.0%) | 0.02% +0.023 pp | 0.04% +0.037 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 78 | CAPITAL ADVISORS INC/OK | 10.0K +— (+0.0%) | 94.0K +34.0K (+56.7%) | 0.02% 0.000 pp | 0.00% +0.001 pp | USD6.00 +56.7% | 2 qtrs — |
| 79 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 7.1K -443.0 (-5.8%) | 67.1K +21.6K (+47.5%) | 0.02% -0.001 pp | 0.01% +0.001 pp | USD3.74 +151.3% | 5 qtrs — |
| 80 | FMR LLC | 7.0K -942.0 (-11.9%) | 65.6K +18.1K (+38.0%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD3.32 +183.1% | 6 qtrs — |
| 81 | TOWER RESEARCH CAPITAL LLC (TRC) | 5.1K -1.2K (-18.6%) | 47.7K +10.3K (+27.6%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD2.96 +217.6% | 8 qtrs — |
| 82 | JPMORGAN CHASE & CO | 4.3K -2.4K (-36.0%) | 40.2K +126.0 (+0.3%) | 0.01% -0.006 pp | 0.00% +0.000 pp | USD12.61 -25.5% | 8 qtrs — |
| 83 | DEUTSCHE BANK AG\ | 3.9K +— (+0.0%) | 36.8K +13.3K (+56.7%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.07 +206.2% | 5 qtrs — |
| 84 | ADVISOR GROUP HOLDINGS, INC. | 3.2K +725.0 (+29.0%) | 30.3K +15.5K (+104.1%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD10.15 -7.4% | 8 qtrs — |
| 85 | ROYAL BANK OF CANADA | 3.3K +1.2K (+61.5%) | 30.0K +18.0K (+150.0%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD7.37 +27.5% | 7 qtrs — |
| 86 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 2.1K +456.0 (+27.3%) | 20.0K +10.0K (+99.4%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD4.88 +92.6% | 5 qtrs — |
| 87 | PNC FINANCIAL SERVICES GROUP, INC. | 1.7K +— (+0.0%) | 15.7K +5.7K (+56.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.21 +325.3% | 4 qtrs — |
| 88 | RUSSELL INVESTMENTS GROUP, LTD. | 1.3K +— (+0.0%) | 12.3K +4.5K (+56.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.36 +298.3% | 5 qtrs — |
| 89 | VERMILLION & WHITE WEALTH MANAGEMENT GROUP, LLC | 1.1K +1.1K (+100.0%) | 10.3K +10.3K (+100.0%) | 0.00% +0.003 pp | 0.01% +0.006 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 90 | GF FUND MANAGEMENT CO. LTD. | 860.00 -38.0 (-4.2%) | 8.1K +2.7K (+50.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.46 +171.7% | 5 qtrs — |
| 91 | NATIONAL BANK OF CANADA /FI/ | 400.00 +400.0 (+100.0%) | 3.8K +3.8K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 92 | NISA INVESTMENT ADVISORS, LLC | 301.00 +— (+0.0%) | 2.8K +1.0K (+56.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.63 +103.0% | 6 qtrs — |
| 93 | TFC FINANCIAL MANAGEMENT, INC. | 300.00 +300.0 (+100.0%) | 2.8K +2.8K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD9.40 +0.0% | 1 qtrs NEW |
| 94 | FOURTH DIMENSION WEALTH, LLC | 250.00 +— (+0.0%) | 2.4K +850.0 (+56.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.74 +151.3% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 52 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Simplify Propel Opportunities ETF SURI | 2.00% | 1.55M | 2.82% |
| 2 | State Street SPDR S&P Kensho New Economies Composite ETF KOMP | 0.08% | 2.21M | 0.20% |
| 3 | iShares Micro-Cap ETF IWC | 0.08% | 1.18M | 0.60% |
| 4 | T. Rowe Price Innovation Leaders ETF TNXT | 0.04% | 7.5K | 0.49% |
| 5 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.04% | 164.1K | 0.40% |
| 6 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.04% | 26.5K | 0.19% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.03% | 375.4K | 0.35% |
| 8 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 25.1K | 0.35% |
| 9 | Fidelity Enhanced Small Cap ETF FESM | 0.03% | 1.50M | 0.28% |
| 10 | iShares Biotechnology ETF IBB | 0.02% | 2.30M | 0.44% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
300.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+300,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Dac Nadia | Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 9.00 | 2.70M | 300,000 | D | ↗ |
| 2026-03-13 | GRASSO MARC | Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 8.95 | 581.8K | 65,000 | D | ↗ |
| 2026-03-13 | GEHCHAN NAJI | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 8.95 | 939.8K | 105,000 | D | ↗ |
| 2026-03-13 | Biddle Warner Weston | Director / Officer | A-Award | A | Stock Option (right to buy) | 350,000 | 8.95 | 3.13M | 350,000 | D | ↗ |
| 2026-02-24 | Miller Andrew Craig | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-02-24 | Emany Sravan Kumar | Director | A-Award | A | Stock Option (right to buy) | 42,945 | 7.95 | 341.4K | 42,945 | D | ↗ |
| 2026-02-09 | Pujols Mayobanex | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-12 | Shaw Christi | Director / Officer | A-Award | A | Common Stock | 24,301 | 0.00 | — | 70,935 | D | ↗ |
| 2025-12-18 | Westlake BioPartners Opportunity Fund I, L.P. | 10% Owner | P-Purchase | A | Common Stock | 133,333 | 7.50 | 1,000.0K | 869,317 | I | ↗ |
| 2025-12-18 | SEIDENBERG BETH C | Director | P-Purchase | A | Common Stock | 133,333 | 7.50 | 1,000.0K | 869,317 | I | ↗ |
| 2025-12-15 | Walker Karen Marie | Officer | S-Sale | D | Common Stock | 23,998 | 12.20 | 292.8K | 22,636 | D | ↗ |
| 2025-06-30 | GRASSO MARC | Officer | A-Award | D | Stock Option (right to buy) | 450,000 | 3.07 | 1.38M | 450,000 | D | ↗ |
| 2025-05-29 | Shaw Christi | Director | A-Award | A | Common Stock | 16,634 | 0.00 | — | 16,634 | D | ↗ |
| 2025-05-29 | SPIEGELMAN DANIEL K | Director | A-Award | A | Stock Option (right to buy) | 65,351 | 2.63 | 171.9K | 65,351 | D | ↗ |
| 2025-05-29 | SEIDENBERG BETH C | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 65,351 | 2.63 | 171.9K | 65,351 | D | ↗ |
| 2025-05-29 | Cohen Fred E | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 65,351 | 2.63 | 171.9K | 65,351 | D | ↗ |
| 2025-05-29 | CLARK IAN T | Director | A-Award | A | Common Stock | 16,634 | 0.00 | — | 16,634 | D | ↗ |
| 2025-05-29 | Aktar Mert | Director | A-Award | A | Stock Option (right to buy) | 65,351 | 2.63 | 171.9K | 65,351 | D | ↗ |
| 2025-04-11 | Walker Karen Marie | Officer | A-Award | A | Common Stock | 13,000 | 0.00 | — | 22,636 | D | ↗ |
| 2025-04-11 | Jones Ryan Alexander | Officer | A-Award | A | Common Stock | 12,000 | 0.00 | — | 55,950 | D | ↗ |
| 2025-02-14 | Shaw Christi | Director | A-Award | A | Stock Option (right to buy) | 38,679 | 3.03 | 117.2K | 38,679 | D | ↗ |
| 2025-01-22 | GEHCHAN NAJI | Officer | A-Award | A | Stock Option (right to buy) | 425,000 | 3.29 | 1.40M | 425,000 | D | ↗ |
| 2024-10-21 | Aktar Mert | Director | A-Award | A | Stock Option (right to buy) | 87,741 | 5.20 | 456.3K | 87,741 | D | ↗ |
| 2024-09-16 | Shaw Christi | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-16 | Biddle Warner Weston | Director / Officer | A-Award | A | Stock Option (right to buy) | 2,579,259 | 6.89 | 17.77M | 2,579,259 | — | ↗ |
| 2024-04-11 | Walker Karen Marie | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 2.06 | 164.8K | 80,000 | D | ↗ |
| 2024-04-11 | Jones Ryan Alexander | Officer | A-Award | A | Stock Option (right to buy) | 74,000 | 2.06 | 152.4K | 74,000 | D | ↗ |
| 2024-04-11 | Biddle Warner Weston | Director / Officer | A-Award | A | Stock Option (right to buy) | 332,500 | 2.06 | 685.0K | 332,500 | D | ↗ |
| 2024-02-12 | GILEAD SCIENCES, INC. | 10% Owner | P-Purchase | A | Common Stock | 910,000 | 22.00 | 20.02M | 4,126,119 | — | ↗ |
| 2024-02-07 | Maag Peter | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 58,220 | — | ↗ |
| 2024-02-07 | Kotzin Brian L. | Director | — | D | Stock Option (Right to Buy) | 32,959 | 4.83 | 159.2K | 0 | — | ↗ |
| 2024-02-07 | GILEAD SCIENCES, INC. | 10% Owner | — | D | Series A-2 Convertible Preferred Stock | 1,514,083 | 0.00 | — | 0 | — | ↗ |
| 2024-02-07 | CLARK IAN T | Director | — | D | Stock Option (Right to Buy) | 38,736 | 4.42 | 171.2K | 0 | — | ↗ |
| 2024-02-07 | Bain Capital Life Sciences Investors, LLC | 10% Owner | — | I | Series B Convertible Preferred Stock | 2,713,868 | 0.00 | — | 0 | — | ↗ |
| 2022-08-28 | Kotzin Brian L. | Director | — | D | Stock Option (Right to Buy) | 43,306 | 0.32 | 13.9K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
43.79M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Naji Gehchan, M.D. Chief Medical and Development Officer | 481.7K | 250.0K | — | 1.11M | 238.4K | 5.0K | 2.09M | 53.24% | ↗ |
| 2 | 2025 | Warner Biddle Chief Executive Officer | 625.0K | — | — | 543.8K | 468.8K | 177.4K | 1.81M | 29.96% | ↗ |
| 3 | 2025 | Marc Grasso, M.D. Chief Financial Officer | 257.0K | 100.0K | — | 1.10M | 204.0K | 2.6K | 1.66M | 66.13% | ↗ |
| 4 | 2024 | Warner Biddle Chief Executive Officer | 182.3K | 650.0K | — | 13.76M | 375.0K | 25.0K | 14.99M | 91.78% | ↗ |
| 5 | 2024 | Peter Maag, Ph.D. Former Chief Executive Officer | 786.5K | — | — | — | — | 694.8K | 1.48M | 0.00% | ↗ |
| 6 | 2024 | James Chung, M.D., Ph.D. Former Chief Medical Officer | 404.6K | — | — | — | — | 220.0K | 624.6K | 0.00% | ↗ |
| 7 | 2024 | Karen Walker Chief Technology Officer | 440.0K | — | — | — | 151.4K | — | 591.4K | 0.00% | ↗ |
| 8 | 2024 | Dominic Borie, M.D., Ph.D. Former President, Research and Development | 440.0K | — | — | — | 147.8K | — | 587.8K | 0.00% | ↗ |
| 9 | 2023 | Peter Maag, Ph.D. Former Chief Executive Officer | 438.9K | 247.5K | — | 1.55M | — | 23.6K | 2.26M | 68.64% | ↗ |
| 10 | 2023 | James Chung, M.D., Ph.D. Former Chief Medical Officer | 402.0K | 153.0K | — | 520.5K | — | 90.6K | 1.17M | 44.64% | ↗ |
| 11 | 2023 | Karen Walker Chief Technology Officer | 387.9K | 150.2K | — | 520.5K | — | 23.6K | 1.08M | 48.10% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Warner Biddle | Chief Executive Officer & Director | 1M | male |
| Naji Gehchan | Chief Medical & Development Officer | 975.1K | — |
| Mayo Pujols | Chief Technology Officer | 591.4K | male |
| Marc Grasso | Chief Financial Officer | 563.5K | — |
| Christi L. Shaw | Executive Chairperson | 144.9K | female |
| Jessica Serra | Head of Investor Relations | — | female |
| Tom Van Blarcom | Senior Vice President & Head of Research | — | — |
| Tracy Rossin | Senior Vice President of Corporate Affairs & Communications and Investor Relations | — | female |
| Dan Maziasz | Chief Business Officer | — | male |
| Cara Bauer | Chief Human Resources Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KYTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
